Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7


Engineered botulinum neurotoxin B with improved binding to human receptors has enhanced efficacy in preclinical models.

Elliott M, Favre-Guilmard C, Liu SM, Maignel J, Masuyer G, Beard M, Boone C, Carré D, Kalinichev M, Lezmi S, Mir I, Nicoleau C, Palan S, Perier C, Raban E, Zhang S, Dong M, Stenmark P, Krupp J.

Sci Adv. 2019 Jan 16;5(1):eaau7196. doi: 10.1126/sciadv.aau7196. eCollection 2019 Jan.


A comparison of biological activity of commercially available purified native botulinum neurotoxin serotypes A1 to F1 in vitro, ex vivo, and in vivo.

Donald S, Elliott M, Gray B, Hornby F, Lewandowska A, Marlin S, Favre-Guilmard C, Périer C, Cornet S, Kalinichev M, Krupp J, Fonfria E.

Pharmacol Res Perspect. 2018 Nov 22;6(6):e00446. doi: 10.1002/prp2.446. eCollection 2018 Dec.


Augmentation of VAMP-catalytic activity of botulinum neurotoxin serotype B does not result in increased potency in physiological systems.

Elliott M, Maignel J, Liu SM, Favre-Guilmard C, Mir I, Farrow P, Hornby F, Marlin S, Palan S, Beard M, Krupp J.

PLoS One. 2017 Oct 5;12(10):e0185628. doi: 10.1371/journal.pone.0185628. eCollection 2017.


Bilateral analgesic effects of abobotulinumtoxinA (Dysport® ) following unilateral administration in the rat.

Favre-Guilmard C, Chabrier PE, Kalinichev M.

Eur J Pain. 2017 May;21(5):927-937. doi: 10.1002/ejp.995. Epub 2017 Mar 6.


Different antinociceptive effects of botulinum toxin type A in inflammatory and peripheral polyneuropathic rat models.

Favre-Guilmard C, Auguet M, Chabrier PE.

Eur J Pharmacol. 2009 Sep 1;617(1-3):48-53. doi: 10.1016/j.ejphar.2009.06.047. Epub 2009 Jul 1. Erratum in: Eur J Pharmacol. 2010 Feb 25;628(1-3):290.


The novel inhibitor of the heterotrimeric G-protein complex, BIM-46187, elicits anti-hyperalgesic properties and synergizes with morphine.

Favre-Guilmard C, Zeroual-Hider H, Soulard C, Touvay C, Chabrier PE, Prevost G, Auguet M.

Eur J Pharmacol. 2008 Oct 10;594(1-3):70-6. doi: 10.1016/j.ejphar.2008.07.016. Epub 2008 Jul 15.


Butyl 2-(4-[1.1'-biphenyl]-4-yl-1H-imidazol-2-yl)ethylcarbamate, a potent sodium channel blocker for the treatment of neuropathic pain.

Liberatore AM, Schulz J, Favre-Guilmard C, Pommier J, Lannoy J, Pawlowski E, Barthelemy MA, Huchet M, Auguet M, Chabrier PE, Bigg D.

Bioorg Med Chem Lett. 2007 Mar 15;17(6):1746-9. Epub 2006 Dec 22.


Supplemental Content

Loading ...
Support Center